公开(公告)号：US20230002770A1

公开(公告)日：2023-01-05

申请号：US17755943

申请日：2020-11-16

申请人： Nogra Pharma Limited

发明人： Francesca Viti ,  Marie McNulty ,  Salvatore Bellinvia

IPC分类号： C12N15/113 ,  A61P1/00

摘要： Disclosed herein are IL-34 inhibitors, including IL-34 antisense oligonucleotide sequences, and methods for treating inflammatory diseases, such as an inflammatory bowel disease, and/or fibrosis, associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing an IL-34 inhibitor, for example, a IL-34 antisense oligonucleotide, useful for treating inflammatory diseases and/or fibrosis and manufacture of medicaments containing a disclosed IL-34 inhibitor to be used in treating inflammatory diseases and/or fibrosis.

公开(公告)号：US20220000818A1

公开(公告)日：2022-01-06

申请号：US17425648

申请日：2020-01-24

申请人： Nogra Pharma Limited

发明人： Salvatore Bellinvia ,  Francesca Viti

IPC分类号： A61K31/196 ,  A61P17/10 ,  A61K9/06

摘要： Disclosed herein are methods for preventing acne in a patient comprising administering topically to the patient a composition effective to induce sebocyte differentiation. Also disclosed herein are methods of preventing acne in a patient comprising administering topically to the patient a composition effective to reduce insulin-induced lipoxygenase (LOX) activity and/or inflammatory processes. Also disclosed herein are methods of preventing a disease, condition, or disorder characterized by alteration of sebocyte differentiation, comprising administering topically to a patient a composition effective to induce sebocyte differentiation. The described methods can include administering a composition that includes a therapeutically effective amount of a PPARγ modulator, and a pharmaceutically acceptable excipient.

公开(公告)号：US20210290656A1

公开(公告)日：2021-09-23

申请号：US17162226

申请日：2021-01-29

申请人： Nogra Pharma Limited

发明人： Sergio Baroni ,  Salvatore Bellinvia ,  Francesca Viti

IPC分类号： A61K31/7125 ,  A61P1/04 ,  A61K9/00 ,  A61K47/38 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/34

摘要： The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.

公开(公告)号：US10272047B2

公开(公告)日：2019-04-30

申请号：US15335198

申请日：2016-10-26

申请人： Nogra Pharma Limited

发明人： Sergio Baroni ,  Salvatore Bellinvia ,  Francesca Viti

IPC分类号： C07H21/04 ,  C07H21/02 ,  A61K48/00 ,  A61K9/28 ,  C12N15/113 ,  A61K31/7125 ,  A61K9/00 ,  A61K31/7105

摘要： The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.

公开(公告)号：US20190046490A1

公开(公告)日：2019-02-14

申请号：US16078555

申请日：2017-02-27

申请人： Nogra Pharma Limited

发明人： Marie McNulty ,  Francesca Viti ,  Salvatore Bellinvia

IPC分类号： A61K31/201 ,  A61P1/00

摘要： Disclosed herein in part are methods for treating lactose intolerance, including administering fatty acid compounds that modulate PPARγ receptors.

公开(公告)号：US20180128829A1

公开(公告)日：2018-05-10

申请号：US15705715

申请日：2017-09-15

申请人： Nogra Pharma Limited

发明人： Giovanni Monteleone ,  Francesca Viti ,  Salvatore Bellinvia

IPC分类号： G01N33/569 ,  G01N33/68 ,  G01N33/50

CPC分类号： G01N33/56972 ,  G01N33/505 ,  G01N33/5094 ,  G01N33/6866 ,  G01N33/6869 ,  G01N33/6872 ,  G01N2333/54 ,  G01N2333/7158 ,  G01N2800/065 ,  G01N2800/52

摘要： Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemsistry, and/or ELISA.

公开(公告)号：US20170158707A1

公开(公告)日：2017-06-08

申请号：US15321967

申请日：2015-06-26

申请人： Nogra Pharma Limited

发明人： Francesca Viti ,  Salvatore Bellinvia ,  Salvatore Demartis

IPC分类号： C07D495/14 ,  C07D471/04 ,  C07D487/04 ,  C07D209/14 ,  C07D209/08 ,  C07D277/64 ,  C07D277/82 ,  C07D495/04 ,  C07D235/30 ,  C07C235/46 ,  C07C235/38 ,  C07C233/73 ,  C07C233/29 ,  C07D213/75 ,  C07D333/36 ,  C07D209/94 ,  C07D209/86

CPC分类号： C07D495/14 ,  C07C233/29 ,  C07C233/73 ,  C07C235/38 ,  C07C235/46 ,  C07D209/08 ,  C07D209/14 ,  C07D209/86 ,  C07D209/94 ,  C07D213/75 ,  C07D235/30 ,  C07D277/64 ,  C07D277/82 ,  C07D333/36 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

摘要： The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-γ in a subject.

公开(公告)号：US20150087678A1

公开(公告)日：2015-03-26

申请号：US14394916

申请日：2013-04-12

申请人： Nogra Pharma Limited

发明人： Sergio Baroni ,  Salvatore Bellinvia ,  Francesca Viti

IPC分类号： A61K31/196 ,  A23C19/09 ,  A23C13/12 ,  A23C21/08 ,  A61K31/4439 ,  A23C9/20

CPC分类号： A61K31/196 ,  A23C9/152 ,  A23C9/20 ,  A23C13/12 ,  A23C19/09 ,  A23C21/08 ,  A61K31/195 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/635

摘要： Disclosed herein are methods for treating lactose intolerance, including compounds that may be specific or modulate PPARγ receptors.

摘要翻译： 本文公开了治疗乳糖不耐症的方法，包括可能是特异性或调节PPARγ受体的化合物。

公开(公告)号：US20180113139A1

公开(公告)日：2018-04-26

申请号：US15329514

申请日：2015-07-28

申请人： Nogra Pharma Limited

发明人： Salvatore Bellinvia ,  Francesca Viti

IPC分类号： G01N33/68 ,  C12Q1/6883

CPC分类号： G01N33/6869 ,  C07K14/54 ,  C07K14/7153 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/54 ,  G01N2800/065 ,  G01N2800/52

摘要： Disclosed herein are methods for diagnosing and/or treating inflammatory bowel diseases associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing an inhibitor of IL-34 useful for treating inflammatory bowel diseases and manufacture of medicaments containing an inhibitor of IL-34 to be used in treating inflammatory bowel disease.

公开(公告)号：US20180065921A1

公开(公告)日：2018-03-08

申请号：US15593864

申请日：2017-05-12

申请人： Nogra Pharma Limited

发明人： Sergio Baroni ,  Salvatore Bellinvia ,  Francesca Viti

IPC分类号： C07C229/44 ,  A61K31/357 ,  A61K31/196 ,  A61K31/343

CPC分类号： C07C229/44 ,  A61K31/196 ,  A61K31/343 ,  A61K31/357 ,  A61P1/04

摘要： The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.